{
    "clinical_study": {
        "@rank": "38409", 
        "acronym": "PROPAH", 
        "arm_group": [
            {
                "arm_group_label": "Phase I Patient Interviews", 
                "description": "Indepth interviews will be completed with approximately 15 patients."
            }, 
            {
                "arm_group_label": "Phase II Patient Questionnaire", 
                "description": "Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I"
            }
        ], 
        "brief_summary": {
            "textblock": "Develop a brief, new, patient reported outcome instrument that is valid for use in clinical\n      practice and clinical trials."
        }, 
        "brief_title": "Patient Reported Outcomes in Pulmonary Arterial Hypertension", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Arterial Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will use the Clinical Impact Method to develop a patient reported outcome for use\n      in patients with pulmonary arterial hypertension Clinical personnel at the study sites will\n      approach and discuss possible participation in Phase I and II of the study with subjects\n      from the existing pool of patients currently receiving usual and customary care at the site."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Evidence of a personally signed and dated informed consent\n\n          -  Subjects aged >=18 who have documented PAH\n\n          -  Speak English\n\n          -  Subjects who provide written informed consent to participate in the study before\n             being screened for the study.\n\n        Exclusion Criteria:\n\n          -  Patients with non-PAH Pulmonary Hypertension\n\n          -  Physical inability to complete the interview process\n\n          -  Subjects who are currently enrolled in an experimental drug study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with pulmonary arterial hypertension"
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01792622", 
            "org_study_id": "A1481296"
        }, 
        "intervention": [
            {
                "arm_group_label": "Phase I Patient Interviews", 
                "description": "Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.", 
                "intervention_name": "Interview", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Phase II Patient Questionnaire", 
                "description": "Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.", 
                "intervention_name": "Questionnaire", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Instrument Development", 
            "Patient Reported Outcomes", 
            "Pulmonary Arterial Hypertension."
        ], 
        "lastchanged_date": "July 31, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481296&StudyName=Patient%20Reported%20Outcomes%20in%20Pulmonary%20Arterial%20Hypertension"
        }, 
        "number_of_groups": "2", 
        "official_title": "Patient Reported Outcomes in Pulmonary Arterial Hypertension", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite symptom score shall be derived from the actual items selected as a result of Phase 2.\nThe final scoring logarithm shall provide a score for each dimension, as well as an anxiety/concern scale derived from single items from each of the dimensions, and a total score.", 
            "measure": "The primary endpoint for the study will be a composite symptom score derived from items in the instrument.", 
            "safety_issue": "No", 
            "time_frame": "Patients in Phase 1 and 2 shall be engaged in the study for approximately one hour's time; Phase 1 will take 3 to 6 weeks, and Phase 2 will proceed until sufficient sample size is obtained (saturation); we anticipate completion by September 2013."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01792622"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Chicago", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Mayo Clinic", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Vanderbilt University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}